Evaluation of a Web-based Decision Aid Tool for Larynx Cancer (T3/T4) Patients.

Launched by MAASTRICHT RADIATION ONCOLOGY · Sep 20, 2017

Keywords

ClinConnect Summary

Laryngeal cancer is the second most common head and neck cancer. Each year about 700 people are diagnosed with larynxcarcinoma in the Netherlands (Van Dijk et.al. 2013).

For patients with laryngeal cancer, various treatment options are available, including surgery, radiotherapy, chemotherapy and endoscopic (laser) treatment. Each option has its own benefits and side effects. The optimal treatment for patients having stage 3 or 4 laryngeal cancer is not unambiguously proven. Different treatment options cause different side effects that may impact the patients' health-related quality of life...

Gender

ALL

Eligibility criteria

• • 1. Larynx cancer patients
• Inclusion Criteria:
• • Larynx cancer: T3 anyN M0, T4 anyN M0
• • Proficient in Dutch
• • minimal 18 years old
• Exclusion Criteria:
• • Patients that do not have a treatment choice (due to contra-indications or other medical reasons)
• • patients with recurrent disease
• • For alpha testing patients that already made there decision are selected. For each treatment option (external beam RT, surgery and chemoradiation) at least 10 patients will be included. For beta testing patients that are facing their decision will be included. Aiming for an effect size of 0.60 for a difference in mean total score on the Decisional Conflict Scale, it would require 45 patients per hospital (pre and post intervention) to determine this effect with alpha 0.05 and power 0.80.
• • 2. Physicians
• • Radiotherapy-oncologists
• • Oncologists
• • General practitioners
• • Nurses For alpha testing at least 10 physicians are selected. For beta testing at least 45 questionnaires are required.
• • 3. Patient organizations and insurance companies Besides patients and physicians, patient organizations and insurance companies will be involved to evaluate barriers and facilitators for implementation in clinical practice.